Neutrophilic dermatoses - Pathomechanistic concepts and therapeutic developments.
Journal
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
ISSN: 1610-0387
Titre abrégé: J Dtsch Dermatol Ges
Pays: Germany
ID NLM: 101164708
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
08
01
2023
accepted:
10
02
2023
medline:
19
4
2023
entrez:
18
4
2023
pubmed:
19
4
2023
Statut:
ppublish
Résumé
Neutrophilic dermatoses are a group of clinically heterogeneous diseases characterized by infiltration of neutrophils in the affected tissue. Skin symptoms comprise a spectrum of wheals, papules, plaques, pustules, nodules and ulcerations often in combination with systemic symptoms. Although the pathogenesis of these diseases has not yet been elucidated in depth, broad pathophysiological and clinical overlaps exist with autoinflammatory syndromes. Additionally, recent years have shown the relevance of the signaling pathways of TNF-α, IL-1, IL-12/23 and IL-17 in neutrophilic dermatoses. In this review, we present four selected neutrophilic dermatoses, namely pyoderma gangraenosum, Sweet syndrome, generalized pustular psoriasis and Schnitzler syndrome, discuss pathophysiological aspects and specifically address novel therapeutic options derived from the most recent pathophysiological findings.
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
374-380Informations de copyright
© 2023 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft.
Références
Arteaga JEC, Gonçalves DLM, Giannotti MA, Samorano LP. Neutrophilic eccrine hidradenitis in a healthy Brazilian child. J Dtsch Dermatol Ges. 2019;17(8):834-836.
Ziemer M, Müller AK, Hein G, et al. Incidence and classification of cutaneous manifestations in rheumatoid arthritis. J Dtsch Dermatol Ges. 2016;14(12):1237-1246.
Al Ghazal P, Körber A, Klode J, Dissemond J. Investigation of new co-factors in 49 patients with pyoderma gangrenosum. J Dtsch Dermatol Ges. 2012;10(4):251-257.
Hasselmann DO, Bens G, Tilgen W, Reichrath J. Pyoderma gangrenosum: clinical presentation and outcome in 18 cases and review of the literature. J Dtsch Dermatol Ges. 2007;5(7):560-564.
Gerbing EK, Metze D, Luger TA, Ständer S. [Interstitial granulomatous dermatitis without arthritis: successful therapy with hydroxychloroquine]. J Dtsch Dermatol Ges. 2003;1(2):137-141.
Kawakami T, Ohashi S, Kawa Y, et al. Elevated serum granulocyte colony-stimulating factor levels in patients with active phase of sweet syndrome and patients with active Behçet disease: implication in neutrophil apoptosis dysfunction. Arch Dermatol. 2004;140(5):570-574.
Patterson James. The vasculopathic reaction pattern. Weedon‘s Skin Pathology 4th ed In: Skin Ws, ed Pt, eds. Philadelphia, PA: Elsevier Churchill Livingstone; 2016.
Bonnekoh H, Scheffel J, Wu J, et al. Skin and systemic inflammation in Schnitzler's syndrome are associated with neutrophil extracellular trap formation. Front Immunol. 2019;10:546.
Satoh TK, Mellett M, Contassot E, French LE. Are neutrophilic dermatoses autoinflammatory disorders? Br J Dermatol. 2018;178(3):603-613.
Marzano AV, Borghi A, Meroni PL, Cugno M. Pyoderma gangrenosum and its syndromic forms: evidence for a link with autoinflammation. Br J Dermatol. 2016;175(5):882-891.
Loock J, Lamprecht P, Timmann C, et al. Genetic predisposition (NLRP3 V198M mutation) for IL-1-mediated inflammation in a patient with Schnitzler syndrome. J Allergy Clin Immunol. 2010;125:500-502.
de Koning HD, van Gijn ME, Stoffels M, et al. Myeloid lineage-restricted somatic mosaicism of NLRP3 mutations in patients with variant Schnitzler syndrome. J Allergy Clin Immunol. 2015;135(2):561-564.
Rowczenio DM, Trojer H, Russell T, et al. Clinical characteristics in subjects with NLRP3 V198M diagnosed at a single UK center and a review of the literature. Arthritis Res Ther. 2013;15(1):R30.
Miyoshi T, Yamashita K, Ohno T, et al. Familial Mediterranean fever gene as a possible modifier of Sweet syndrome with chronic myelogenous leukemia. Acta Haematol. 2008;120(1):57-62.
Oskay T, Anadolu R. Sweet's syndrome in familial Mediterranean fever: possible continuum of the neutrophilic reaction as a new cutaneous feature of FMF. J Cutan Pathol. 2009;36(8):901-905.
Maronese CA, Pimentel MA, Li MM, et al. Pyoderma gangrenosum: An updated literature review on established and emerging pharmacological treatments. Am J Clin Dermatol. 2022;23(5):615-634.
AWMF. S1-Leitlinie Pyoderma gangrenosum. 2020. Available from https://register.awmf.org/assets/guidelines/013-091l_S1_Pyoderma-gangrenosum_2020-10_1.pdf [Last accessed February 9, 2023].
von den Driesch P. Sweet's syndrome (acute febrile neutrophilic dermatosis). J Am Acad Dermatol. 1994;31(4):535-556; quiz 557-560.
Heath MS, Ortega-Loayza AG. Insights into the pathogenesis of Sweet's syndrome. Front Immunol. 2019;10:414.
Garcovich S, De Simone C, Berti E, Marzano AV. Drug management of neutrophilic dermatoses. Expert Rev Clin Pharmacol. 2017;10(10):1119-1128.
Kluger N, Gil-Bistes D, Guillot B, Bessis D. Efficacy of anti-interleukin-1 receptor antagonist anakinra (Kineret®) in a case of refractory Sweet's syndrome. Dermatology. 2011;222(2):123-127.
Joshi TP, Friske SK, Hsiou DA, Duvic M. New Practical Aspects of Sweet Syndrome. Am J Clin Dermatol. 2022;23(3):301-318.
Reich K, Augustin M, Gerdes S, et al. Generalized pustular psoriasis: overview of the status quo and results of a panel discussion. J Dtsch Dermatol Ges. 2022;20(6):753-771.
Bachelez H, Choon SE, Marrakchi S, et al. Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis. N Engl J Med. 2019;380(10):981-983.
Schön M, Wilsmann-Theis D. Current developments and perspectives in psoriasis. J Dtsch Dermatol Ges. 2023;21(4):363-373.
Simon A, Asli B, Braun-Falco M, et al. Schnitzler's syndrome: diagnosis, treatment, and follow-up. Allergy. 2013;68(5):562-568.
Betrains A, Staels F, Vanderschueren S. Efficacy and safety of canakinumab treatment in schnitzler syndrome: A systematic literature review. Semin Arthritis Rheum. 2020;50(4):636-642.
Quaranta M, Knapp B, Garzorz N, et al. Intraindividual genome expression analysis reveals a specific molecular signature of psoriasis and eczema. Sci Transl Med. 2014;6(244):244ra90.
Dreisewerd K, Bien T, Soltwisch J. MALDI-2 and t-MALDI-2 mass spectrometry imaging. Methods Mol Biol. 2022;2437:21-40.
Ronicke M, Baur A, Kirr M, et al. C. Epidermotropism of inflammatory cells differentiates pyoderma gangrenosum from venous leg ulcers. J Dtsch Dermatol Ges. 2022;20(5):619-627.
Shimokata M, Munetsugu T, Okuzawa M, et al. Schnitzler syndrome with basophil infiltration. J Dtsch Dermatol Ges. 2020;18(9):1034-1036.
Bonnekoh H, Scheffel J, Maurer M, Krause K. Use of skin biomarker profiles to distinguish Schnitzler syndrome from chronic spontaneous urticaria: results of a pilot study. Br J Dermatol. 2018;178(2):561-562.
Calabrese L, Caldarola G, Peris K, De Simone C. Recalcitrant Sweet syndrome successfully treated with adalimumab. J Dtsch Dermatol Ges. 2021;19(1):122-124.
Krueger J, Puig L, Thaçi D. Treatment options and goals for patients with generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):51-64.
Arnold DD, Yalamanoglu A, Boyman O. Systematic review of safety and efficacy of IL-1-targeted biologics in treating immune-mediated disorders. Front Immunol. 2022;13:888392.
Krause K, Feist E, Fiene M, Kallinich T, Maurer M. Complete remission in 3 of 3 anti-IL-6-treated patients with Schnitzler syndrome. J Allergy Clin Immunol. 2012:848-850.
Claus J, Vanderschueren S. Variable responses to tocilizumab in four patients with schnitzler syndrome. J Clin Immunol. 2019;39(4):370-372.
Yan R, Cao W, Liu X, et al. A Chinese case series of Schnitzler syndrome and complete remission in one tocilizumab-treated patient. Clin Rheumatol. 2020;39(12):3847-3852.
Bonnekoh H, Frischbutter S, Roll S, et al. Tocilizumab treatment in patients with Schnitzler syndrome: An open-label study. J Allergy Clin Immunol Pract. 2021;9(6):2486-2489.e4.
Kooybaran NR, Korsten P, Schön MP, Mössner R. Response of rheumatoid arthritis-associated pyoderma gangrenous to the JAK1 inhibitor upadacitinib. J Dtsch Dermatol Ges. 2022;20(4):522-524.
Li M, Chen YW, Shen A, et al. Case report: Successful treatment with tofacitinib and colchicine in a patient with Schnitzler syndrome. Int J Rheum Dis. 2023;26(1):160-163.
Jani P, Vissing MB, Ahmed S, et al. Ibrutinib for the management of Schnitzler Syndrome: a novel therapy for a rare condition. J Oncol Pract. 2018;14(6):387-388.
Claves F, Siest R, Lefebvre C, et al. Dramatic efficacy of ibrutinib in a Schnitzler syndrome case with indolent lymphoma. J Clin Immunol. 2021;41(6):1380-1383.
Huang Y, Wang Y, Yu F, et al. Case report: therapeutic use of ibrutinib in a patient with Schnitzler syndrome. Front Immunol. 2022;13:894464.